Abstract Library

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience

Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,

Keywords: mcc, avelumab, activity, safety,

#2960 Epidemiological Characteristics of Neuroendocrine Tumors: A Retrospective Analysis of a Single Centre

Introduction: Neuroendocrine tumors (NETs) are a small heterogeneous group of cancers, developing from the neuroendocrine system. NETs may include functional or non-functional tumors; moreover, they may be familial and have further associated tumors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Blanco G, Sciacca D, Colarossi C, Leotta E,

Keywords: neuroendocrine, tumors, our, retrospective, analysis,

#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience

Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,

Keywords: somatostatin, analogs, interval, reduction, experience, elderly,

#2151 Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis

Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Giuffrida D

Authors: Giuffrida D, Chillari F, Blanco G, Russo A, Franchina T,

Keywords: neuroendocrine carcinoma, lung, platinum-etoposide, LCNEC, SCLC, chemotherapy,